. Author manuscript; available in PMC: 2016 Nov 3.

Published in final edited form as: J Am Coll Cardiol. 2015 Nov 3;66(18):2053–2055. doi: 10.1016/j.jacc.2015.08.866

Table 1.

Association of APOC3 Loss-of-Function Mutation Carrier Status with Blood Lipid Levels and Subclinical Atherosclerosis

	Non-Carriers (N=6,331)	Carriers (N=64)	Effect Estimate	95% CI	P-value
Blood Lipids
Triglycerides (mg/dL)^*	166.1 ± 96.2	91.2 ± 44.1	−43.7%	−36.6, −49.9	1.83 × 10⁻²¹
HDL Cholesterol (mg/dL)	55.6 ± 15.2	66.6 ± 15.0	+11.1	7.6, 14.6	3.55 × 10⁻¹⁰
LDL Cholesterol (mg/dL)	130.3 ± 36.4	131.6 ± 35.8	+1.5	−7.4, 10.3	0.75

Subclinical Atherosclerosis
Coronary Arterial Calcification (Agatston Units)^†	46.0 (0.0, 245.0)	29.0 (0.0, 227.5)	−27.9	−51.1, −4.7	0.019
Carotid Plaque (mm²)^†	183.8 (0.0, 555.9)	112.8 (0.0, 367.2)	−8.7	−73.5, 56.0	0.79
Carotid Intima Media Thickness (mm)^*	0.76 ± 0.16	0.74 ± 0.13	−1.7%	−6.3, 3.0	0.47

HDL = high-density lipoprotein; LDL = low-density lipoprotein; CI = confidence interval

Values are represented as effect estimates (95% confidence intervals) between APOC3 loss-of-function mutation carriers and non-carriers after adjustment for covariates. Covariates used were age, sex, ancestry, and principal components of ancestry.

Effect estimates for triglycerides and carotid intima media thickness were derived from natural log transformation and are expressed as percent difference in carriers compared with non-carriers.

^†

Effect estimates for coronary arterial calcification and carotid plaque derived from median quantile regression and represent differences in medians. Therefore, summary statistics of the distributions in non-carriers and carriers are represented as median (interquartile range).